Aequus Pharmaceuticals (CVE:AQS) Trading Down 25%

Aequus Pharmaceuticals Inc. (CVE:AQS) shares dropped 25% during mid-day trading on Tuesday . The stock traded as low as C$0.02 and last traded at C$0.02. Approximately 168,000 shares were traded during trading, a decline of 7% from the average daily volume of 181,409 shares. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Stock Down 25.0 %

The company has a debt-to-equity ratio of 138.88, a current ratio of 0.09 and a quick ratio of 0.46. The stock has a market capitalization of C$1.99 million, a PE ratio of -1.50 and a beta of 0.05. The company has a 50 day moving average price of C$0.02 and a 200-day moving average price of C$0.02.

Aequus Pharmaceuticals Company Profile

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.